• Jade Biosciences entered a worldwide, exclusive license with Paragon Therapeutics for certain antibodies targeting an undisclosed target across all therapeutic areas.
• Deal includes up to $22 million in development and regulatory milestones, including $2.5 million due at first Phase 1 patient dosing.
• Paragon also becomes eligible for up to about $20.1 million per product in sublicensing fees, mainly tied to commercial milestones.
• Paragon earns low- to mid-single-digit royalties on annual net sales of monospecific products, mid-single-digit royalties on multispecific products.
• Paragon agreed to refrain from new antibody campaigns against the target in the field for at least five years.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jade Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-292704), on July 01, 2026, and is solely responsible for the information contained therein.